• / Free eNewsletters & Magazine
  • / My Account

AES

SPDR® S&P Homebuilders ETF XHB 2 Star

Last Price$35.53Day Change (%)0.82%
Open Price$35.30Day Change ($)0.29
Day Range35.21–35.5552-Week Range27.72–36.66

As of Thu 12/8/2016 12:11:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan

    Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan

  2. Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

    Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

  3. Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

    Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

  4. Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

    Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

  5. Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology

    Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology

  6. New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

    New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

  7. Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection

    Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection

  8. Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting

    Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting

  9. Top Holdings of Four All-Weather Ultimate Stock-Pickers

    While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.

  10. What to Do With Exelon?

    Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.